166 related articles for article (PubMed ID: 12923193)
1. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
Metz TO; Alderson NL; Chachich ME; Thorpe SR; Baynes JW
J Biol Chem; 2003 Oct; 278(43):42012-9. PubMed ID: 12923193
[TBL] [Abstract][Full Text] [Related]
2. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine.
Onorato JM; Jenkins AJ; Thorpe SR; Baynes JW
J Biol Chem; 2000 Jul; 275(28):21177-84. PubMed ID: 10801874
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Metz TO; Alderson NL; Thorpe SR; Baynes JW
Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
[TBL] [Abstract][Full Text] [Related]
5. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
[TBL] [Abstract][Full Text] [Related]
6. Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Padival S; Nagaraj RH
Ophthalmic Res; 2006; 38(5):294-302. PubMed ID: 16974131
[TBL] [Abstract][Full Text] [Related]
7. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.
Kang Z; Li H; Li G; Yin D
Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947
[TBL] [Abstract][Full Text] [Related]
8. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.
Muellenbach EA; Diehl CJ; Teachey MK; Lindborg KA; Archuleta TL; Harrell NB; Andersen G; Somoza V; Hasselwander O; Matuschek M; Henriksen EJ
Metabolism; 2008 Oct; 57(10):1465-72. PubMed ID: 18803954
[TBL] [Abstract][Full Text] [Related]
9. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation.
Voziyan PA; Metz TO; Baynes JW; Hudson BG
J Biol Chem; 2002 Feb; 277(5):3397-403. PubMed ID: 11729198
[TBL] [Abstract][Full Text] [Related]
10. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Nagaraj RH; Sarkar P; Mally A; Biemel KM; Lederer MO; Padayatti PS
Arch Biochem Biophys; 2002 Jun; 402(1):110-9. PubMed ID: 12051689
[TBL] [Abstract][Full Text] [Related]
11. Glycoxidation and lipoxidation in atherogenesis.
Baynes JW; Thorpe SR
Free Radic Biol Med; 2000 Jun; 28(12):1708-16. PubMed ID: 10946212
[TBL] [Abstract][Full Text] [Related]
12. Inhibition effect of pyridoxamine on lipid hydroperoxide-derived modifications to human serum albumin.
Lee SH; Matsunaga A; Oe T
PLoS One; 2018; 13(4):e0196050. PubMed ID: 29672562
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Wu ET; Liang JT; Wu MS; Chang KC
Exp Gerontol; 2011 Jun; 46(6):482-8. PubMed ID: 21316441
[TBL] [Abstract][Full Text] [Related]
14. Chelating activity of advanced glycation end-product inhibitors.
Price DL; Rhett PM; Thorpe SR; Baynes JW
J Biol Chem; 2001 Dec; 276(52):48967-72. PubMed ID: 11677237
[TBL] [Abstract][Full Text] [Related]
15. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.
Curtis TM; Hamilton R; Yong PH; McVicar CM; Berner A; Pringle R; Uchida K; Nagai R; Brockbank S; Stitt AW
Diabetologia; 2011 Mar; 54(3):690-8. PubMed ID: 21116609
[TBL] [Abstract][Full Text] [Related]
16. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.
Voziyan PA; Khalifah RG; Thibaudeau C; Yildiz A; Jacob J; Serianni AS; Hudson BG
J Biol Chem; 2003 Nov; 278(47):46616-24. PubMed ID: 12975371
[TBL] [Abstract][Full Text] [Related]
17. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Alderson NL; Chachich ME; Frizzell N; Canning P; Metz TO; Januszewski AS; Youssef NN; Stitt AW; Baynes JW; Thorpe SR
Diabetologia; 2004 Aug; 47(8):1385-95. PubMed ID: 15309289
[TBL] [Abstract][Full Text] [Related]
18. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.
Stitt A; Gardiner TA; Alderson NL; Canning P; Frizzell N; Duffy N; Boyle C; Januszewski AS; Chachich M; Baynes JW; Thorpe SR
Diabetes; 2002 Sep; 51(9):2826-32. PubMed ID: 12196477
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
Voziyan PA; Hudson BG
Cell Mol Life Sci; 2005 Aug; 62(15):1671-81. PubMed ID: 15905958
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats.
Figarola JL; Scott S; Loera S; Xi B; Synold T; Rahbar S
Ann N Y Acad Sci; 2005 Jun; 1043():767-76. PubMed ID: 16037304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
